exactly - market macros have no relationship to the company development going forward - the market is always wrong that's why correctly pricing the value of this company to the current sp makes it a buy in anyone's terms - you must correctly assess that equation... guessing a floor or a top is a wasted futile exercise - the zeros will pile on the end of each of IHLs' drug candidates worth as they progress through the phase III trials....
bring on 2023
IHL Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held